Objective: The objective of this study was to examine the relationship between adherence to treatment with sodium channel blockers (SCBs) and health-related quality of life (HRQoL), work productivity and activity impairment (WPAI), healthcare resource utilization (HRU), and associated costs among patients with epilepsy. Methods: This retrospective cross-sectional study used data from the 2017 US National Health and Wellness Survey (NHWS; N = 75,004). Health-related quality of life (Study Short-Form 36-Item Health Survey version 2 [SF36v2]), WPAI (Work Productivity and Activity Impairment-General Health [WPAI-GH] questionnaire), HRU, and annual costs were compared among respondents with epilepsy using SCBs categorized as low/medium adherence (n = 120) and high adherence (n = 80) using generalized linear models, controlling for patient characteristics. Results: Mental component score, Short-Form 6-Dimension (SF-6D) health utility index, bodily pain, mental health, physical functioning, role emotional, social functioning, and vitality scores were significantly lower in low/medium adherence respondents than in high adherence respondents (for all, p b 0.05). Only activity impairment was significantly higher in low/medium adherence respondents compared with the high adherence group (p b 0.001). Healthcare resource utilization did not differ significantly between the two groups; however, the number of emergency room (ER) visits and total costs were lower in the high adherence group (p = 0.038) compared with the low/medium adherence group (p = 0.040). Conclusion: High adherence to SCBs was associated with improved HRQoL, lower WPAI, and lower HRU and associated costs among patients with epilepsy. Therefore, adherence to SCBs may be an important factor in improving the abovementioned patient-reported outcomes. Findings from this study can help provide further impetus to healthcare policymakers and clinicians for addressing the low antiepileptic drug (AED) adherence levels in adult patients with epilepsy.
Introduction
Epilepsy is a disorder of the brain characterized by seizures that may be caused by a host of factors including developmental abnormalities, genetic disorders, fever, infections, severe head trauma, brain tumors, stroke, neurologic or metabolic disorders, alcohol withdrawal, illicit drug use, and even pharmacotherapeutic substances [1] . In the US, the prevalence of active epilepsy among adults has increased from 1.0% (2.3 million cases) in 2010 [2] to 1.2% (3 million cases) in 2015 [3] , with men and women being affected equally [4] . The age-adjusted mortality rate for epilepsy as any-listed cause of death from 2005 to 2014 increased from 0.58 to 0.85 per 100,000, which is a 47% increase during this period in the US [5] .
Apart from impacting mortality rates, epilepsy is also associated with a significant debilitating effect of morbidity resulting in reduced health-related quality of life (HRQoL) [6] . Additionally, epilepsy adversely affects work productivity and activity impairment (WPAI) [7] . Furthermore, patients with epilepsy face a high economic burden due to increased healthcare resource utilization (HRU) and associated costs [7] . Treatment adherence is known to be a significant predictor of long-term outcomes related to seizure frequency reduction, morbidity, and HRQoL. Nonadherence to antiepileptic drugs (AEDs) among patients with epilepsy ranges from 26% to 79% [8] , and the impact of nonadherence is not inconsequential. Poor adherence to AEDs results in lower quality of life (QoL), increased mortality, emergency department visits, hospitalizations, fractures, head injuries, and costs as reported in claims-based studies and survey research [9, 10, 11] .
Sodium channel blockers (SCBs) have been used to treat epilepsy since 1938 [12] and are commonly used as a first-line therapy for epilepsy in the US [13] . Moreover, new third-generation SCB AEDs with potentially unique or different mechanisms of action and with fewer or no known pharmacokinetic drug interactions have been introduced recently [12, 14] . Although AED class and treatment aspects (e.g., tolerability and dosage) and their association with nonadherence have been studied, little is known about the variation in SCB adherence levels.
As SCBs have a well-defined dose-related set of adverse events, it is important to understand whether good adherence with SCBs is associated with better HRQoL, suggesting that any adverse events related to SCBs did not override the benefits of better seizure control with better adherence. Therefore, the objective of this study was to examine the relationship between adherence to treatment with SCBs and HRQoL, WPAI, HRU, and associated costs among patients with epilepsy.
Methods

Sample
This retrospective cross-sectional study was conducted using data from the 2017 US National Health and Wellness Survey (NHWS; N = 75,004), a survey designed to examine health in the general adult population (age ≥18 years). Potential NHWS respondents were identified from an Internet-based panel maintained by Lightspeed Research and recruited using a stratified random sampling to mirror the age and gender distribution of the general US adult population (based on data from the most recent US Census). Participants were considered to be eligible for the study if they were (1) able to read and understand English, (2) able to operate a computer to access the online survey, (3) located in the US, (4) aged 18 years or older, and (5) willing to provide informed consent to participate in the study. Respondents who self-reported an epilepsy diagnosis from a healthcare provider (n = 774) were categorized into those currently using monotherapy (i.e., only a single prescription medication was used) SCBs or other medications (Fig. 1) . The final analyses were conducted only among patients receiving SCBs.
The study was found to be exempt from review by the Pearl Institutional Review Board (Indianapolis, IN, USA). Informed consent was provided by all the respondents.
Measures
Adherence status
Respondents on SCBs were categorized into two groups based on their adherence status using the Morisky Medication Adherence Scale (©MMAS-8) [15] as low/medium adherence (©MMAS-8 score b8; n = 120) and high adherence (©MMAS-8 score 8; n = 80). 1 
Demographics and health characteristics
Demographic measures included age (continuous), gender (male or female), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or other ethnicity), education (b4-year college degree or ≥ 4-year college degree), marital status (single/married/living with partner/divorced/separated/widowed/decline to answer), annual household income (b$25,000, $25,000-$50,000, $50,000-$75,000, ≥$75,000, or declined to answer), labor force participation (yes or no), and health insurance status (yes or no).
Health characteristics data included smoking status (current smoker, former smoker, or never smoked), exercise for more than 20 min in the past month (zero times or more than once time), alcohol use (yes or no), body mass index (BMI) [16] , and the Charlson Comorbidity Index (CCI) [17] .
Epilepsy characteristics
Data on the epilepsy type (idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy, symptomatic partial epilepsy, or unknown), frequency of seizures (more than once a week, once a week, two to three times a month, once a month, every three months, every six months, once a year, less than once a year), years diagnosed with epilepsy, and number of seizures in the past six months and past 30 days were collected.
Health-related quality of life
Physical component summary (PCS), mental component summary (MCS), and Short-Form 6-Dimension (SF-6D) health utility index scores, as well as scores for eight health subdomains from the Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36) version 2 (SF-36v2) were used to assess the HRQoL [18, 19] . The MCS and PCS are normed to the US general population (mean = 50.00, standard deviation [SD] = 10.00) and range from 0 to 100 whereas the SF-6D health utility index scores range from zero to one. Higher scores signify better HRQoL for all these measures. Minimally important differences (MIDs) for the MCS/PCS and SF-6D health utility index scores were represented by three and 0.041 points, respectively [18, 20] .
Work productivity and activity impairment
Work productivity loss and activity impairment were assessed using the Work Productivity and Activity Impairment-General Health (WPAI-GH) questionnaire, a six-item instrument consisting of four domains (absenteeism, presenteeism, overall work impairment, and activity impairment) [21] . The scores are represented as percentages, with higher values indicating greater impairment in the patient's health for the past seven days. While only currently employed respondents (fulltime, part-time, or self-employed) provided the data on absenteeism, presenteeism, and overall work impairment, the data on activity impairment were provided by all the respondents.
Healthcare resource utilization
Self-reported number of all-cause traditional provider visits, emergency room (ER) visits, and hospitalizations in the past six months were used to measure the HRU.
Costs
Indirect and direct costs were estimated from the available NHWS data. The estimated annual direct costs included all-cause HRU costs and were extrapolated from the Medical Expenditure Panel Survey [22] by applying 2014 age-specific unit cost to each HRU event of the NHWS respondents. Similarly, the annual indirect costs were determined by extrapolation, where 2014-specific wages from the Bureau of Labor Statistics [23] were applied to work hours lost with presenteeism and absenteeism from the WPAI-GH. Estimated total costs were calculated as a sum of direct and indirect costs. For respondents who were unemployed, their estimated total costs did not include indirect costs.
Statistical analyses
Bivariate analyses
Descriptive statistics (means and SD for continuous variables and frequencies and percentages for categorical variables) were reported for all the study outcomes differentiated by adherence levels (low/medium vs high adherence) to SCBs. Chi-square and one-way analysis of variance tests (ANOVAs) were used to determine the significant differences (p b 0.05, two-tailed) for categorical and continuous variables, respectively. These results served to characterize differences between those with low/medium adherence and high adherence and advised the selection of the covariates for multivariable analyses.
Multivariable analyses
Generalized linear models (GLMs) that specify a normal distribution and identity function were used for normally distributed outcome variables (e.g., HRQoL) whereas GLMs that specify a negative binomial distribution and a log-link function were used for highly positively skewed outcome variables (e.g., WPAI, HRU, and costs) to test whether any statistically significant (p b 0.05, two-tailed) differences existed between the two adherence groups on the outcomes of interest, controlling for covariates. Covariates utilized in this study included age, gender, ethnicity, years diagnosed with epilepsy, and number of seizures in the past six months. Estimated means, standard errors, confidence intervals, and p-values were reported by adherence groups (low/medium adherence vs high adherence).
Results
Demographics and disease characteristics by adherence levels among SCB users (unadjusted results)
Of the 200 respondents included in the study analyses, average age was reported to be 49 years, with 55% being female and 69% nonHispanic white. The most common type of epilepsy reported by them was idiopathic generalized epilepsy (46.5%), followed by symptomatic partial epilepsy (focal epilepsy, temporal lobe epilepsy, frontal lobe epilepsy; 19.0%), and the patients on SCBs had an average CCI score of 0.82 (Table 1) .
Patients in the high adherence group tended to be older and had been diagnosed with epilepsy for a longer period of time than those with low/medium adherence (p b 0.001, for both). A higher proportion of non-Hispanic whites were observed among the high adherence group compared with the low/medium adherence group (p = 0.048). In addition, the high adherence group was less likely to be in the labor force and consumed alcohol (p = 0.025 and p = 0.020, respectively; Table 1 ). The number of seizures in the past six months and in the past 30 days did not differ by adherence levels. However, the percentage of patients experiencing less than one seizure per year was 66.3% in the high adherence group vs 50% in the low adherence group (Table 2) .
HRQoL, WPAI, HRU, and costs by adherence levels among SCB users (unadjusted results)
High adherence levels were associated with significantly greater MCS, SF-6D health utility index, mental health, role emotional, social functioning, vitality (p b 0.001 for all); bodily pain (p = 0.010); general health (p = 0.007); physical functioning (p = 0.039); and role physical (p = 0.040), and the differences reached MIDs, except for PCS. Presenteeism and activity impairment scores were higher among those with low/medium adherence compared with those who had high adherence (p = 0.041 and p b 0.001, respectively). The number of ER visits differed significantly by adherence, with patients with low/medium adherence having three times the number of ER visits compared with those with high adherence (p = 0.008). Consequently, ER costs among those with low/medium adherence were three times as high as those with high adherence (p = 0.009). No other costs were significantly different between the two adherence groups (Table 3) . (Fig. 2) . While absenteeism, presenteeism, and overall work impairment did not differ significantly, activity impairment in the low/medium adherence group was two times higher than in the high adherence group (p b 0.001; Fig. 3 ). Although HRU did not differ significantly between the groups (Fig. 4) , the ER costs ($801 vs $2366) and the total costs ($19,535 vs $36,151) were significantly lower in the high adherence group than in the low/medium adherence group (p = 0.038 and p = 0.040, respectively; Fig. 5 ).
Discussion
Epilepsy can be adequately treated with medication in approximately 70% of patients [24] . However, studies have revealed that nonadherence to AEDs is highly prevalent among American adults (26%-46.40%) [10, 11, 25] . Nonadherent patients with epilepsy report more difficulty in attaining seizure control than adherent patients. In addition, uncontrolled seizures result in major morbidity and mortality [26] . While SCB AEDs were shown to have greater adherence rates compared with non-SCB AEDs [27] , this study evaluated the association between varying SCB adherence levels and patient-reported outcomes such as HRQoL, WPAI, HRU, and costs among patients with epilepsy.
In this study, older, non-Hispanic whites, employed respondents, and patients who did not consume alcohol were highly adherent to SCBs compared with their counterparts, indicating that these characteristics may be related to better treatment access and continuity of care. Indeed, an earlier study reported that Caucasians showed better adherence to AEDs compared with African-Americans [28] . Furthermore, in concordance with Sweileh et al. [29] , this study found that older patients and patients with longer duration of epilepsy showed higher adherence to AEDs, possibly due to the patients' realization of the benefits of adherence to their medications through time.
Epilepsy is a neurologic condition that results in significant health consequences, economic burden, and decreased productivity of patients worldwide [30] . Previous research in the US has shown that patients with epilepsy had significantly lower HRQoL compared with the general population [31] . In the current study, HRQoL was lower in patients with low/medium adherence to SCBs and with decreased scores for most of the SF-36 components. Consistent with these results, a prior study reported that patients with low/medium adherence showed lower MCS and health utility scores compared with those who had high adherence [32] . Similarly, a cross-sectional study in the US reported reduced HRQoL in nonadherent patients compared with adherent patients [11] . Activity impairment in the current study was higher in respondents with low/medium adherence than those with high adherence. A recent study by Gupta et al. [7] reported that greater seizure frequency is directly correlated with an increase in absenteeism, presenteeism, and WPAI in the US and other countries. The same study reported that patients with lower seizure frequency showed less activity impairment compared with respondents having higher seizure frequency [7] .
A retrospective study conducted in the US population reported that nonadherence was associated with an increased incidence of hospitalizations and emergency department visits [10] . Although not statistically significant, the number of traditional provider and ER visits in this study was higher in the low/medium adherence group than the high adherence group.
It has been shown that patients with epilepsy have more chronic comorbid conditions, which in turn results in significantly higher number of medical provider visits and prescription medications and higher Table 3 Health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and costs by adherence levels among SCB users. unadjusted average healthcare expenditures (direct costs of illness) [33] . A systematic review of the economic impact of epilepsy stated that studies that evaluated both direct and indirect costs concluded the latter to often be a greater burden than the former [10] . Consistent with the increased HRU, the findings of this study reported an increase in direct costs in the low/medium adherence group compared with high adherence group. Similarly, Ip et al. [34] reported that total direct healthcare costs for AED-adherent elderly patients having Medicare benefits in the US was 13.2% less than those of nonadherent individuals. In sum, study findings are in line with the larger set of research examining the benefits of high adherence to treatments. However, research on the effect of adherence on patient-reported outcomes by specific classes of AEDs is limited. Thus, the contribution of the current study is the specific examination of whether patient-reported outcomes differ by adherence levels to SCBs among patients with epilepsy.
Limitations
The present study has a few limitations. The NHWS is an observational cross-sectional study, preventing causal conclusions from being drawn.
However, a cross-sectional study design allows for capturing a specific point in time and the examination of a multitude of patient-reported outcomes in an expedient manner. As is with any research, study findings may be biased because of unknown factors, and therefore, caution needs to be taken while interpreting the data. However, the present analyses adjust for many confounders that may adversely impact the strength of the findings. The use of self-reported measures may lead to inaccurate recall of information. However, the panel took adequate measures to minimize false reporting. Furthermore, the survey was relatively low-stakes and benign, as questionnaire were simple and not designed to be intrusive or offensive. Notwithstanding its limitations, self-reported measures are critical for understanding the impact of treatments and adherence to treatments among patients as only patients themselves can report on their QoL or work productivity loss. In addition, more than one-third of all patients with epilepsy had idiopathic generalized epilepsy. The use of SCBs among this type of epilepsy may exacerbate certain types of primary generalized seizures, and therefore, these patients may be skewed towards the use of only one or two SCBs like lamotrigine. It should be noted that the reliability of the reported epilepsy characteristics of this study might be low as the respondents might have failed to understand *** Fig. 3 . Work productivity and activity impairment by SCB adherence level, adjusted for covariates. Note: Covariates analyzed in this study included age, gender (male vs female), race/ ethnicity (others vs white), years diagnosed with epilepsy, and number of seizures in the past 6 months. p-Values represent post hoc pairwise comparisons of adjusted means. pValues for the low/medium adherence group versus the high adherence group: ***p ≤ 0.001. their seizure types and could have incorrectly reported them. In future research, this analysis should be repeated with patients with epilepsy who do not have idiopathic generalized epilepsy. In the current study, SCBs were examined as a class; further research could examine how the type of SCBs, dosage, and therapeutic complexities may impact adherence and outcomes. Lastly, the current study focused only on SCB adherence levels and its association with outcomes as the research was scarce on this topic. Further research is needed to examine the variation in adherence levels among other classes of AEDs and its association with patient-reported outcomes.
Conclusion
This study demonstrated that high adherence to SCBs was associated with clinically meaningful HRQoL improvement, decrease in activity impairment, and lower HRU and related costs. Therefore, adherence to SCBs may be an important factor in improving the abovementioned patient-reported outcomes. Findings from this study can help provide further impetus to healthcare policymakers and clinicians for addressing the low AED adherence levels in adult patients with epilepsy. Further efforts can be concentrated on breaking down barriers such as dosing schedule (e.g., monotherapy or once-daily regimens), titration, and economic burden on the patients. Future research could consider how to improve the adherence among patients with epilepsy who have been prescribed SCBs.
Ethical statement
We confirm that we have read the journal's position on ethical publication and confirm that this publication is consistent with those guidelines.
